Alcobra Ltd. (ADHD) Shares Down 4%
Alcobra Ltd. (NASDAQ:ADHD)’s share price fell 4% on Wednesday . The company traded as low as $4.32 and last traded at $4.36, with a volume of 68,938 shares traded. The stock had previously closed at $4.54.
A number of brokerages have recently weighed in on ADHD. Zacks Investment Research lowered Alcobra from a “buy” rating to a “hold” rating in a research report on Wednesday, April 27th. Roth Capital reiterated a “buy” rating and set a $12.00 price target on shares of Alcobra in a report on Tuesday, June 21st. Canaccord Genuity initiated coverage on Alcobra in a report on Tuesday, June 7th. They set a “buy” rating for the company. Finally, Cantor Fitzgerald initiated coverage on Alcobra in a report on Tuesday, June 7th. They set a “buy” rating and a $16.00 price target for the company. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $10.63.
The firm’s market capitalization is $119.07 million. The stock’s 50-day moving average price is $4.77 and its 200 day moving average price is $4.71.
Alcobra (NASDAQ:ADHD) last issued its quarterly earnings data on Monday, May 16th. The company reported ($0.18) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.04. Analysts expect that Alcobra Ltd. will post ($0.98) earnings per share for the current fiscal year.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.